CERCAM

Across TCGA pan-cancer cohorts, CERCAM mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated CERCAM data layer compared with 24 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CERCAM mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CERCAM expression acts as an unfavorable survival marker, although some lineages such as HNSC show a favorable association.

HNSC, LSCC, and PDAC are the cancer types where CERCAM mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.882	0.682	.001	70	view →
LSCC	DFS	Quartile	II,III,IV	0.608	0.939	.012	24	view →
PDAC	OS	Median	III,IV	0.286	0.611	.003	16	view →
LUAD	OS	Quartile	All	0.557	1.000	.030	6	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

CERCAM–HNSC (DFS)

Open the HNSC breakdown →